• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Indivior PLC

    11/14/24 5:00:25 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INDV alert in real time by email
    SC 13G/A 1 form_sc13ga-indivior.htm

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
    Indivior PLC
    (Name of Issuer)
    Ordinary Shares, $0.50 nominal value per share
    (Title of Class of Securities)
    G4766E116
    (CUSIP Number)
    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ☐ Rule 13d-1(b)
    ☐ Rule 13d-1(c)
    ☒ Rule 13d-1(d)

    (1)
    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be “filed’ for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    CUSIP No. G4766E116
                 
    1.
     
    NAME OF REPORTING PERSONS:
     
    Scopia Capital Management LP
    2.
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
     
    (a) ☐ (b) ☐
    3.
     
    SEC USE ONLY
     
    4.
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
    WITH
     
    5.
     
    SOLE VOTING POWER
     
    0
     
    6.
     
    SHARED VOTING POWER
     
    2,088,554
     
    7.
     
    SOLE DISPOSITIVE POWER
     
    0
     
    8.
     
    SHARED DISPOSITIVE POWER
     
    2,088,554
    9.
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,088,554
    10.
     
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
    11.
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    1.6%
    12.
     
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
    PN, IA



    CUSIP No. G4766E116
                 
    1.
     
    NAME OF REPORTING PERSONS:
     
    Scopia Management, Inc.
    2.
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
     
    (a) ☐ (b) ☐
    3.
     
    SEC USE ONLY
     
    4.
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    New York
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
    WITH
     
    5.
     
    SOLE VOTING POWER
     
    0
     
    6.
     
    SHARED VOTING POWER
     
    2,088,554
     
    7.
     
    SOLE DISPOSITIVE POWER
     
    0
     
    8.
     
    SHARED DISPOSITIVE POWER
     
    2,088,554
    9.
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,088,554
    10.
     
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
    11.
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    1.6%
    12.
     
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
    CO, HC



    CUSIP No. G4766E116
                 
    1.
     
    NAME OF REPORTING PERSONS:
     
    Matthew Sirovich
    2.
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
     
    (a) ☐ (b) ☐
    3.
     
    SEC USE ONLY
     
    4.
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
    WITH
     
    5.
     
    SOLE VOTING POWER
     
    3,423,067
     
    6.
     
    SHARED VOTING POWER
     
    2,088,554
     
    7.
     
    SOLE DISPOSITIVE POWER
     
    3,423,067
     
    8.
     
    SHARED DISPOSITIVE POWER
     
    2,088,554
    9.
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    5,511,621
    10.
     
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
    11.
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    4.3%
    12.
     
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
    IN, HC



    CUSIP No. G4766E116
                 
    1.
     
    NAME OF REPORTING PERSONS:
     
    Jeremy Mindich
    2.
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
     
    (a) ☐ (b) ☐
    3.
     
    SEC USE ONLY
     
    4.
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
    WITH
     
    5.
     
    SOLE VOTING POWER
     
    0
     
    6.
     
    SHARED VOTING POWER
     
    2,088,554
     
    7.
     
    SOLE DISPOSITIVE POWER
     
    0
     
    8.
     
    SHARED DISPOSITIVE POWER
     
    2,088,554
    9.
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,088,554
    10.
     
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
    11.
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    1.6%
    12.
     
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
    IN, HC



    CUSIP No. G4766E116

             
    Item 1.
     
    (a).
     
    Name of Issuer:
         
           
    Indivior PLC (the “Issuer”)
         
       
    (b).
     
    Address of Issuer’s Principal Executive Offices:
         
           
    10710 Midlothian Turnpike, Suite 125
    North Chesterfield, VA  23235
         
    Item 2.
     
    (a).
     
    Name of Person Filing:
         
           
    Scopia Capital Management LP
    Scopia Management, Inc.
    Matthew Sirovich
    Jeremy Mindich
         
       
    (b).
     
    Address or Principal Business Office or, if None, Residence:
         
           
    Scopia Capital Management LP
    152 West 57th Street, 33rd Floor
    New York, NY 10019
     
    Scopia Management, Inc.
    Matthew Sirovich
    Jeremy Mindich
    c/o Scopia Capital Management LP
    152 West 57th Street, 33rd Floor
    New York, NY 10019
         
       
    (c).
     
    Citizenship:
         
           
    Scopia Capital Management LP is a Delaware limited partnership
    Scopia Management, Inc. is a New York corporation
    Matthew Sirovich is a United States citizen
    Jeremy Mindich is a United States citizen
         
       
    (d).
     
    Title of Class of Securities:
         
           
    Ordinary Shares, $0.50 nominal value per share (“Ordinary Shares”)
         
       
    (e).
     
    CUSIP Number:
         
           
    G4766E116
       
    Item 3.
     
    If this statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a:
         
       
    (a) ☐
     
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
         
       
    (b) ☐
     
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).


                         
       
    (c)
     
    ☐
     
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
       
    (d)
     
    ☐
     
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
       
    (e)
     
    ☒
     
    An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
       
    (f)
     
    ☐
     
    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
       
    (g)
     
    ☒
     
    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
       
    (h)
     
    ☐
     
    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
           
       
    (i)
     
    ☐
     
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
       
    (j)
     
    ☐
     
    A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
           
       
    (k)
     
    ☐
     
    Group, in accordance with §240.13d-1(b)(1)(ii)(K).
     
    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:
       
    Item 4.
     
    Ownership.
           
       
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
           
           
       
    Scopia Capital Management LP
           
         
       
    (a)
     
    Amount beneficially owned as of September 30, 2024:
         
           
    2,088,554
         
       
    (b)
     
    Percent of class as of September 30, 2024:
         
           
    1.6%
         
       
    (c)
     
    Number of shares as of September 30, 2024, as to which the person has:
             
           
    (i)
     
    Sole power to vote or to direct the vote
     
    0,
             
           
    (ii)
     
    Shared power to vote or to direct the vote
     
    2,088,554,
             
           
    (iii)
     
    Sole power to dispose or to direct the disposition of
     
    0,
             
           
    (iv)
     
    Shared power to dispose or to direct the disposition of
     
    2,088,554.


                     
    Scopia Management, Inc.
       
    (a)
     
    Amount beneficially owned as of September 30, 2024:
       
       
    2,088,554
       
    (b)
     
    Percent of class as of September 30, 2024:
       
       
    1.6%
       
    (c)
     
    Number of shares as of September 30, 2024, as to which the person has:
           
       
    (i)
     
    Sole power to vote or to direct the vote
     
    0,
           
       
    (ii)
     
    Shared power to vote or to direct the vote
     
    2,088,554,
           
       
    (iii)
     
    Sole power to dispose or to direct the disposition of
     
    0,
           
       
    (iv)
     
    Shared power to dispose or to direct the disposition of
     
    2,088,554.
       
    Matthew Sirovich
       
       
    (a)
     
    Amount beneficially owned as of September 30, 2024:
       
       
    5,511,621
       
    (b)
     
    Percent of class as of September 30, 2024:
       
       
    4.3%
       
    (c)
     
    Number of shares as of September 30, 2024, as to which the person has:
           
       
    (i)
     
    Sole power to vote or to direct the vote
     
    3,423,067,
           
       
    (ii)
     
    Shared power to vote or to direct the vote
     
    2,088,554,
           
       
    (iii)
     
    Sole power to dispose or to direct the disposition of
     
    3,423,067,
           
       
    (iv)
     
    Shared power to dispose or to direct the disposition of
     
    2,088,554.
       
    Jeremy Mindich
       
       
    (a)
     
    Amount beneficially owned as of September 30, 2024:
       
       
    2,088,554

                         
         
       
    (b)
     
    Percent of class as of September 30, 2024:
       
       
    1.6%
         
       
    (c)
     
    Number of shares as of September 30, 2024, as to which the person has:
             
           
    (i)
     
    Sole power to vote or to direct the vote
     
    0,
             
           
    (ii)
     
    Shared power to vote or to direct the vote
     
    2,088,554,
             
           
    (iii)
     
    Sole power to dispose or to direct the disposition of
     
    0,
             
           
    (iv)
     
    Shared power to dispose or to direct the disposition of
     
    2,088,554.
       
    Item 5.
     
    Ownership of Five Percent or Less of a Class.
       
       
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].
         
       
    Item 6.
     
    Ownership of More Than Five Percent on Behalf of Another Person.
       
       
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
       
       
    N/A
       
    Item 7.
     
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
       
    If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary.
       
       
    N/A
       
    Item 8.
     
    Identification and Classification of Members of the Group.
       
       
    If a group has filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §§ 240.13d-1(c) or §§ 240.13d-1(d), attach an exhibit stating the identity of each member of the group.
       
      N/A



       
    Item 9.
     
    Notice of Dissolution of Group.
       
       
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.
       
       
    N/A
       
    Item 10.
     
    Certification.
       
       
    N/A.


    SIGNATURES

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.
    Dated:  November 14, 2024
     
    SCOPIA CAPITAL MANAGEMENT LP
       
     
    By:
    Scopia Management, Inc.
    General Partner
         
     
    By:
    /s/ Matthew Sirovich
       
    Name:
    Matthew Sirovich
       
    Title:
    Managing Director


     
    SCOPIA MANAGEMENT, INC.
         
     
    By:
    /s/ Matthew Sirovich
       
    Name:
    Matthew Sirovich
       
    Title:
    Managing Director


      /s/ Matthew Sirovich
     
    MATTHEW SIROVICH


      /s/ Jeremy Mindich
     
    JEREMY MINDICH


    Get the next $INDV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INDV

    DatePrice TargetRatingAnalyst
    1/28/2025$16.00Buy
    Rodman & Renshaw
    7/23/2024$22.00Overweight
    Piper Sandler
    4/3/2024$37.00Buy
    Craig Hallum
    7/13/2023$35.00Outperform
    Northland Capital
    More analyst ratings

    $INDV
    Financials

    Live finance-specific insights

    See more
    • Indivior Announces Q1 2025 Financial Results

      SLOUGH, United Kingdom and RICHMOND, Va., April 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending March 31, 2025. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at www.indivior.com/investorsThe investor presentation can be found at www.indivior.com/investors (at 7:00 am ET)There will be a live webcast presentation at 13:00 BST (8:00 am ET) hosted by Mark Crossley, CEO. The details are below. Webcast link: https://edge.media-server.com

      4/24/25 2:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior Announces FY and Q4 2024 Financial Results

      SLOUGH, United Kingdom and RICHMOND, Va., Feb. 20, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending December 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at www.indivior.com/investorsThe investor presentation can be found at www.indivior.com/investors (at 7:00 am ET)There will be a live webcast presentation at 13:00 BST (8:00 am ET) hosted by Mark Crossley, CEO. The details are below. Webcast link: https://edge.media-server.c

      2/20/25 2:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior Announces Q3 2024 Financial Results

      SLOUGH, United Kingdom and RICHMOND, Va., Oct. 24, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending September 30, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at www.indivior.com/investorsThe investor presentation can be found at www.indivior.com/investors (at 7:00 am ET)There will be a live webcast presentation at 13:00 BST (8:00 am ET) hosted by Mark Crossley, CEO. The details are below. Webcast link: https://edge.media-server.

      10/24/24 2:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Indivior to Participate in Upcoming Investor Events

      RICHMOND, Va., May 13, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ/LSE: INDV) today announced that it will participate in the following investor events: Jefferies Global Healthcare Conference – New York City, NYJoe Ciaffoni, Chief Executive Officer, and Ryan Preblick, Chief Financial Officer, will host 1x1 / group meetings on Wednesday, June 4th. Joe Ciaffoni will also participate in a fireside discussion on Wednesday, June 4th at 9:55 a.m. U.S. ET. Interested investors should contact their Jefferies representative to schedule a meeting. The fireside discussion will be publicly

      5/13/25 10:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy

      SUBLOCADE use during pregnancy showed no increased risk of birth defects, miscarriage, or maternal complications compared to general population rates RICHMOND, Va., May 1, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the publication of a study "Monthly Buprenorphine Depot Injection (SUBLOCADE) for Opioid Use Disorder During Pregnancy" in the American Journal on Addictions, evaluating the use of SUBLOCADE for the treatment of opioid use disorder (OUD) during pregnancy and postpartum. Three sources of data evaluated in this retrospective study illustrated that the use of monthly SUBLOCADE during pregnancy demonstrated no increased risk and is consistent with the establi

      5/1/25 10:27:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior Announces Q1 2025 Financial Results

      SLOUGH, United Kingdom and RICHMOND, Va., April 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending March 31, 2025. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at www.indivior.com/investorsThe investor presentation can be found at www.indivior.com/investors (at 7:00 am ET)There will be a live webcast presentation at 13:00 BST (8:00 am ET) hosted by Mark Crossley, CEO. The details are below. Webcast link: https://edge.media-server.com

      4/24/25 2:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on Indivior with a new price target

      Rodman & Renshaw initiated coverage of Indivior with a rating of Buy and set a new price target of $16.00

      1/28/25 7:14:13 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Indivior with a new price target

      Piper Sandler initiated coverage of Indivior with a rating of Overweight and set a new price target of $22.00

      7/23/24 6:29:18 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Craig Hallum initiated coverage on Indivior with a new price target

      Craig Hallum initiated coverage of Indivior with a rating of Buy and set a new price target of $37.00

      4/3/24 7:45:35 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Indivior PLC

      SC 13G - INDIVIOR PLC (0001625297) (Subject)

      11/15/24 6:03:54 PM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Indivior PLC

      SC 13G/A - INDIVIOR PLC (0001625297) (Subject)

      11/14/24 5:00:25 PM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Indivior PLC

      SC 13D/A - INDIVIOR PLC (0001625297) (Subject)

      11/7/24 8:23:16 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDV
    Leadership Updates

    Live Leadership Updates

    See more
    • Indivior Announces Further Changes to Board of Directors

      RICHMOND, Va., March 4, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ / LSE: INDV) ("Indivior" or the "Company") today announced that, further to the announcement on December 17, 2024 of certain Director arrangements agreed with Oaktree Capital Management L.P. ("Oaktree"), the announcement on January 28, 2025 of the appointment of Dr. David Wheadon as Chair of the Company, the announcement on February 3, 2025 of the appointment of Daniel Ninivaggi as an Independent Non-Executive Director of the Company, and the announcement on February 27, 2025 of the appointment of Joe Ciaffoni as Chief Executive Officer of the Company, and following further discussions with Oaktree, the Company has agreed to m

      3/4/25 8:40:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDV
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Indivior PLC

      SCHEDULE 13G/A - INDIVIOR PLC (0001625297) (Subject)

      5/13/25 8:50:25 PM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior PLC filed SEC Form 8-K: Leadership Update, Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - INDIVIOR PLC (0001625297) (Filer)

      5/8/25 12:21:52 PM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Indivior PLC

      SCHEDULE 13G/A - INDIVIOR PLC (0001625297) (Subject)

      5/6/25 3:52:41 PM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care